We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
RPL23 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.98
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.014
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
9%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
9%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
1175.0
Number of samples
141
Samples
Sample
Description
TPM
TCGA-14-0871-01A
74 years, female, white, stage:'--, dead, 880 days
2678.5
TCGA-06-2569-01A
24 years, female, black or african american, stage:'--, alive, 13 days
2508.8
TCGA-28-5218-01A
63 years, male, white, stage:'--, dead, 157 days
2436.7
TCGA-06-5417-01A
45 years, female, white, stage:'--, alive, 155 days
2420.7
TCGA-02-2483-01A
43 years, male, asian, stage:'--, alive, 466 days
2352.7
TCGA-41-5651-01A
59 years, female, black or african american, stage:'--, dead, 460 days
1980.8
TCGA-27-2521-01A
34 years, male, white, stage:'--, dead, 510 days
1926.3
TCGA-19-5960-01A
56 years, male, white, stage:'--, dead, 455 days
1834.9
TCGA-19-2629-01A
60 years, male, white, stage:'--, dead, 737 days
1670.5
TCGA-02-0055-01A
62 years, female, white, stage:'--, dead, 76 days
1668.6
TCGA-14-1823-01A
58 years, female, white, stage:'--, dead, 543 days
1662.8
TCGA-06-5416-01A
23 years, female, white, stage:'--, alive, 204 days
1637.8
TCGA-06-0178-01A
38 years, male, white, stage:'--, dead, 2681 days
1619.2
TCGA-27-2524-01A
56 years, male, white, stage:'--, dead, 231 days
1608.9
TCGA-02-2486-01A
64 years, male, white, stage:'--, dead, 618 days
1561.3
TCGA-06-2570-01A
21 years, female, white, stage:'--, alive, 958 days
1555.7
TCGA-28-5207-01A
71 years, male, white, stage:'--, dead, 343 days
1542.5
TCGA-26-5133-01A
59 years, male, white, stage:'--, alive, 452 days
1536.1
TCGA-14-2554-01A
52 years, female, white, stage:'--, dead, 532 days
1506.5
TCGA-06-0138-01A
43 years, male, white, stage:'--, dead, 737 days
1494.2
TCGA-06-0139-01A
40 years, male, white, stage:'--, dead, 362 days
1483.1
TCGA-12-0616-01A
36 years, female, white, stage:'--, dead, 448 days
1478.8
TCGA-28-5216-01A
52 years, male, white, stage:'--, alive, 415 days
1473.1
TCGA-12-5299-01A
56 years, female, white, stage:'--, dead, 98 days
1459.7
TCGA-27-1835-01A
53 years, female, white, stage:'--, dead, 648 days
1446.6
TCGA-06-5413-01A
67 years, male, white, stage:'--, alive, 268 days
1419.3
TCGA-28-5208-01A
52 years, male, white, stage:'--, dead, 544 days
1414.7
TCGA-06-5856-01A
58 years, male, white, stage:'--, dead, 114 days
1414.5
TCGA-32-5222-01A
66 years, male, white, stage:'--, dead, 585 days
1412.5
TCGA-27-1831-01A
66 years, male, white, stage:'--, dead, 505 days
1412.4
TCGA-26-1442-01A
43 years, male, white, stage:'--, alive, 953 days
1392.9
TCGA-06-0129-01A
30 years, male, asian, stage:'--, dead, 1024 days
1390.1
TCGA-14-0817-01A
69 years, female, white, stage:'--, dead, 164 days
1380.9
TCGA-27-2528-01A
62 years, male, white, stage:'--, dead, 480 days
1350.5
TCGA-32-2634-01A
82 years, male, white, stage:'--, alive, 693 days
1350.2
TCGA-14-1829-01A
57 years, male, black or african american, stage:'--, alive, 218 days
1346.0
TCGA-19-4065-01A
36 years, male, white, stage:'--, alive, 214 days
1333.8
TCGA-27-2526-01A
79 years, female, white, stage:'--, dead, 87 days
1315.6
TCGA-02-2485-01A
53 years, male, black or african american, stage:'--, alive, 470 days
1307.2
TCGA-06-0238-01A
46 years, male, white, stage:'--, dead, 405 days
1307.0
TCGA-06-5408-01A
54 years, female, white, stage:'--, dead, 357 days
1293.8
TCGA-76-4925-01A
76 years, male, white, stage:'--, dead, 146 days
1291.1
TCGA-06-5412-01A
78 years, female, white, stage:'--, dead, 138 days
1288.6
TCGA-06-5410-01A
72 years, female, white, stage:'--, dead, 108 days
1269.3
TCGA-27-1832-01A
59 years, female, white, stage:'--, dead, 300 days
1268.3
TCGA-12-5295-01A
60 years, female, white, stage:'--, dead, 454 days
1262.3
TCGA-06-0686-01A
53 years, male, white, stage:'--, dead, 432 days
1255.1
TCGA-32-1982-01A
76 years, female, white, stage:'--, dead, 142 days
1249.5
TCGA-06-0210-01A
72 years, female, white, stage:'--, dead, 225 days
1235.0
TCGA-14-1825-01A
70 years, male, white, stage:'--, dead, 232 days
1234.8
TCGA-28-5209-01A
66 years, female, white, stage:'--, alive, 442 days
1230.7
TCGA-06-0645-01A
55 years, female, white, stage:'--, dead, 175 days
1217.4
TCGA-76-4927-01A
58 years, male, white, stage:'--, dead, 535 days
1188.9
TCGA-14-0789-01A
54 years, male, white, stage:'--, dead, 342 days
1184.9
TCGA-28-5204-01A
72 years, male, white, stage:'--, dead, 454 days
1173.6
TCGA-27-2519-01A
48 years, male, white, stage:'--, dead, 550 days
1169.4
TCGA-06-0174-01A
54 years, male, white, stage:'--, dead, 98 days
1160.8
TCGA-32-2615-01A
62 years, male, white, stage:'--, dead, 485 days
1153.5
TCGA-41-2571-01A
89 years, male, white, stage:'--, dead, 26 days
1143.4
TCGA-06-0745-01A
59 years, male, white, stage:'--, dead, 239 days
1138.2
TCGA-26-5135-01A
72 years, female, white, stage:'--, dead, 270 days
1134.8
TCGA-12-0618-01A
49 years, male, white, stage:'--, dead, 395 days
1130.0
TCGA-27-2523-01A
63 years, male, white, stage:'--, dead, 489 days
1125.1
TCGA-19-1390-01A
63 years, female, white, stage:'--, dead, 772 days
1124.1
TCGA-27-1834-01A
56 years, male, white, stage:'--, dead, 1233 days
1116.5
TCGA-41-3915-01A
48 years, male, white, stage:'--, dead, 360 days
1110.8
TCGA-15-1444-01A
21 years, male, white, stage:'--, dead, 1537 days
1109.3
TCGA-27-1830-01A
57 years, male, white, stage:'--, dead, 154 days
1108.0
TCGA-06-2558-01A
75 years, female, white, stage:'--, dead, 380 days
1106.1
TCGA-16-0846-01A
85 years, male, white, stage:'--, dead, 119 days
1102.9
TCGA-19-2625-01A
76 years, female, white, stage:'--, dead, 124 days
1097.2
TCGA-19-2624-01A
51 years, male, white, stage:'--, dead, 5 days
1094.7
TCGA-06-5411-01A
51 years, male, white, stage:'--, dead, 254 days
1090.0
TCGA-06-0749-01A
50 years, male, black or african american, stage:'--, dead, 82 days
1087.8
TCGA-28-5215-01A
62 years, female, white, stage:'--, dead, 335 days
1086.1
TCGA-19-2620-01A
70 years, male, white, stage:'--, dead, 148 days
1067.0
TCGA-06-0750-01A
43 years, male, white, stage:'--, dead, 28 days
1066.4
TCGA-06-5418-01A
75 years, female, white, stage:'--, dead, 83 days
1060.6
TCGA-06-5858-01A
45 years, female, white, stage:'--, alive, 187 days
1060.5
TCGA-12-0821-01A
62 years, male, white, stage:'--, dead, 323 days
1054.7
TCGA-06-0219-01A
67 years, male, white, stage:'--, dead, 22 days
1054.4
TCGA-28-5220-01A
67 years, male, white, stage:'--, dead, 388 days
1051.1
TCGA-06-0130-01A
54 years, male, white, stage:'--, dead, 394 days
1049.5
TCGA-32-2638-01A
67 years, male, white, stage:'--, dead, 766 days
1048.5
TCGA-76-4931-01A
70 years, female, white, stage:'--, dead, 279 days
1045.3
TCGA-76-4932-01A
50 years, female, white, stage:'--, dead, 1458 days
1040.2
TCGA-06-0168-01A
59 years, female, white, stage:'--, dead, 598 days
1038.8
TCGA-12-3652-01A
60 years, male, white, stage:'--, dead, 1062 days
1036.6
TCGA-32-1980-01A
72 years, male, white, stage:'--, dead, 36 days
1029.7
TCGA-26-5139-01A
65 years, female, white, stage:'--, alive, 48 days
1026.1
TCGA-28-2513-01A
69 years, female, white, stage:'--, alive, 222 days
1024.6
TCGA-06-2559-01A
83 years, male, white, stage:'--, dead, 150 days
1022.4
TCGA-06-0132-01A
49 years, male, white, stage:'--, dead, 771 days
1019.4
TCGA-06-5859-01A
63 years, male, white, stage:'--, alive, 139 days
1018.3
TCGA-32-2616-01A
48 years, female, white, stage:'--, dead, 224 days
1008.3
TCGA-06-2563-01A
72 years, female, white, stage:'--, alive, 932 days
1006.9
TCGA-32-2632-01A
80 years, male, white, stage:'--, dead, 269 days
1002.4
TCGA-06-0156-01A
57 years, male, white, stage:'--, dead, 178 days
995.5
TCGA-06-2565-01A
59 years, male, asian, stage:'--, dead, 506 days
995.3
TCGA-06-0125-01A
63 years, female, white, stage:'--, dead, 1448 days
994.0
TCGA-14-1034-01A
60 years, female, stage:'--, dead, 485 days
988.6
TCGA-28-1753-01A
53 years, male, white, stage:'--, alive, 37 days
986.6
TCGA-26-5132-01A
74 years, male, white, stage:'--, alive, 286 days
985.8
TCGA-06-0747-01A
53 years, male, white, stage:'--, dead, 82 days
982.3
TCGA-06-0644-01A
71 years, male, black or african american, stage:'--, dead, 384 days
974.9
TCGA-06-0744-01A
66 years, male, white, stage:'--, dead, 1426 days
970.0
TCGA-12-3650-01A
46 years, male, white, stage:'--, dead, 333 days
952.4
TCGA-06-2562-01A
81 years, male, white, stage:'--, dead, 382 days
945.5
TCGA-28-2509-01A
77 years, female, white, stage:'--, alive, 145 days
939.5
TCGA-06-2564-01A
50 years, male, white, stage:'--, alive, 181 days
935.9
TCGA-41-2572-01A
67 years, male, white, stage:'--, dead, 406 days
929.5
TCGA-76-4929-01A
76 years, female, white, stage:'--, dead, 111 days
923.4
TCGA-06-2557-01A
76 years, male, black or african american, stage:'--, dead, 33 days
917.0
TCGA-14-0787-01A
69 years, male, asian, stage:'--, dead, 68 days
914.6
TCGA-15-0742-01A
65 years, male, white, stage:'--, dead, 419 days
910.9
TCGA-27-1837-01A
36 years, male, white, stage:'--, dead, 427 days
898.3
TCGA-06-0184-01A
63 years, male, white, stage:'--, dead, 2126 days
888.5
TCGA-28-2514-01A
45 years, male, asian, stage:'--, alive, 160 days
879.1
TCGA-06-0190-01A
62 years, male, white, stage:'--, dead, 317 days
865.2
TCGA-06-2567-01A
65 years, male, white, stage:'--, dead, 133 days
856.8
TCGA-06-0646-01A
60 years, male, white, stage:'--, dead, 175 days
821.9
TCGA-06-5414-01A
61 years, male, white, stage:'--, alive, 273 days
816.7
TCGA-19-2619-01A
55 years, female, black or african american, stage:'--, alive, 294 days
803.6
TCGA-06-0141-01A
62 years, male, white, stage:'--, dead, 313 days
799.4
TCGA-02-0047-01A
78 years, male, white, stage:'--, dead, 448 days
795.5
TCGA-32-1970-01A
59 years, male, white, stage:'--, dead, 468 days
794.3
TCGA-06-0211-01A
47 years, male, white, stage:'--, dead, 360 days
743.2
TCGA-06-2561-01A
53 years, female, white, stage:'--, dead, 537 days
736.7
TCGA-06-0158-01A
73 years, male, white, stage:'--, dead, 329 days
733.8
TCGA-06-0743-01A
69 years, male, white, stage:'--, dead, 803 days
727.7
TCGA-06-0882-01A
30 years, male, white, stage:'--, dead, 632 days
725.1
TCGA-12-3653-01A
34 years, female, white, stage:'--, dead, 442 days
724.9
TCGA-06-0157-01A
63 years, female, white, stage:'--, dead, 97 days
721.4
TCGA-08-0386-01A
74 years, male, white, stage:'--, dead, 548 days
720.7
TCGA-06-0187-01A
69 years, male, white, stage:'--, dead, 828 days
713.9
TCGA-32-4213-01A
47 years, female, white, stage:'--, alive, 604 days
707.6
TCGA-12-0619-01A
60 years, male, white, stage:'--, dead, 1062 days
698.8
TCGA-06-0878-01A
74 years, male, white, stage:'--, alive, 218 days
657.8
TCGA-41-4097-01A
63 years, female, white, stage:'--, dead, 6 days
656.0
TCGA-06-1804-01A
81 years, female, white, stage:'--, dead, 414 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
RPL23 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: 0.99
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
0.021
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
63%
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
20%
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
46.5
Number of samples
58
Samples
Sample
Description
TPM
AK124
N, NA, stage:NA, alive, 1920 days
97.4
AK142
N, NA, stage:NA, alive, 90 days
86.3
AK066
N, NA, stage:NA, alive, 960 days
85.8
AK043
N, NA, stage:NA, alive, 660 days
73.7
AK195
N, NA, stage:NA, dead, 390 days
65.0
AK183
N, NA, stage:NA, alive, 360 days
64.9
AK185
N, NA, stage:NA, alive, 330 days
63.8
AK231
N, NA, stage:NA, dead, 240 days
60.8
AK156
N, NA, stage:NA, dead, 330 days
57.7
AK139
N, NA, stage:NA, dead, 270 days
56.9
AK199
N, NA, stage:NA, alive, 1860 days
55.7
AK041
N, NA, stage:NA, alive, 810 days
55.2
AK165
N, NA, stage:NA, alive, 360 days
54.8
AK030
N, NA, stage:NA, dead, 120 days
54.1
AK002
N, NA, stage:NA, dead, 570 days
53.4
AK003
N, NA, stage:NA, dead, 600 days
53.2
AK188
N, NA, stage:NA, alive, 420 days
52.9
AK133
N, NA, stage:NA, dead, 360 days
52.8
AK055
N, NA, stage:NA, dead, 240 days
52.0
AK051
N, NA, stage:NA, dead, 360 days
51.5
AK173
N, NA, stage:NA, dead, 180 days
51.4
AK049
N, NA, stage:NA, dead, 180 days
50.7
AK134
N, NA, stage:NA, dead, 360 days
50.1
AK205
N, NA, stage:NA, dead, 120 days
49.7
AK074
N, NA, stage:NA, alive, 300 days
49.7
AK178
N, NA, stage:NA, dead, 240 days
46.3
AK213
N, NA, stage:NA, alive, 2010 days
46.1
AK072
N, NA, stage:NA, dead, 150 days
45.8
AK068
N, NA, stage:NA, alive, 360 days
44.3
AK071
N, NA, stage:NA, dead, 540 days
44.0
AK218
N, NA, stage:NA, dead, 180 days
43.4
AK098
N, NA, stage:NA, dead, 660 days
42.9
AK216
N, NA, stage:NA, dead, 360 days
42.4
AK015
N, NA, stage:NA, alive, 720 days
39.4
AK053
N, NA, stage:NA, dead, 300 days
39.1
AK236
N, NA, stage:NA, dead, 360 days
38.3
AK117
N, NA, stage:NA, dead, 210 days
38.1
AK123
N, NA, stage:NA, dead, 180 days
37.2
AK158
N, NA, stage:NA, dead, 360 days
37.0
AK153
N, NA, stage:NA, dead, 240 days
36.6
AK149
N, NA, stage:NA, dead, 420 days
36.1
AK079
N, NA, stage:NA, dead, 210 days
35.6
AK227
N, NA, stage:NA, alive, 300 days
35.2
AK103
N, NA, stage:NA, alive, 1320 days
35.0
AK076
N, NA, stage:NA, alive, 660 days
34.8
AK035
N, NA, stage:NA, dead, 210 days
34.5
AK081
N, NA, stage:NA, dead, 180 days
34.5
AK167
N, NA, stage:NA, dead, 180 days
34.2
AK005
N, NA, stage:NA, dead, 240 days
33.8
AK102
N, NA, stage:NA, alive, 1740 days
32.9
AK091
N, NA, stage:NA, dead, 210 days
32.2
AK099
N, NA, stage:NA, dead, 420 days
31.5
AK085
N, NA, stage:NA, alive, 660 days
30.9
AK088
N, NA, stage:NA, dead, 360 days
30.7
AK100
N, NA, stage:NA, alive, 960 days
30.0
AK089
N, NA, stage:NA, dead, 330 days
29.6
AK226
N, NA, stage:NA, dead, 360 days
25.3
AK006
N, NA, stage:NA, dead, 360 days
22.1
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0217000004
Tumor
0.6
CPT0127480003
Tumor
0.6
CPT0162020003
Tumor
0.5
CPT0206560003
Tumor
0.5
CPT0218690004
Tumor
0.5
CPT0217710008
Tumor
0.4
CPT0127420003
Tumor
0.4
CPT0224540004
Tumor
0.4
CPT0162100003
Tumor
0.4
CPT0182580003
Tumor
0.4
CPT0190360004
Tumor
0.3
CPT0206230003
Tumor
0.3
CPT0125570003
Tumor
0.3
CPT0205570003
Tumor
0.3
CPT0205780003
Tumor
0.3
CPT0167640003
Tumor
0.3
CPT0093510003
Tumor
0.3
CPT0217060003
Tumor
0.2
CPT0087950003
Tumor
0.2
CPT0221180003
Tumor
0.2
CPT0186100003
Tumor
0.2
CPT0078580003
Tumor
0.2
CPT0168830003
Tumor
0.2
CPT0087570003
Tumor
0.2
CPT0205450004
Tumor
0.2
CPT0093360003
Tumor
0.2
CPT0064650003
Tumor
0.2
CPT0208980003
Tumor
0.2
CPT0189650004
Tumor
0.2
CPT0219080004
Tumor
0.2
CPT0224390004
Tumor
0.2
CPT0175060003
Tumor
0.2
CPT0189750004
Tumor
0.2
CPT0167530003
Tumor
0.2
CPT0189460003
Tumor
0.1
CPT0125510003
Tumor
0.1
CPT0168080003
Tumor
0.1
CPT0168380003
Tumor
0.1
CPT0168590003
Tumor
0.1
CPT0093550003
Tumor
0.1
CPT0079790003
Tumor
0.1
CPT0228220003
Tumor
0.1
CPT0182500003
Tumor
0.1
CPT0087680003
Tumor
0.1
CPT0206780003
Tumor
0.1
CPT0167970003
Tumor
0.1
CPT0216920008
Tumor
0.1
CPT0205670004
Tumor
0.1
CPT0087730003
Tumor
0.1
CPT0089150003
Tumor
0.1
CPT0217100003
Tumor
0.1
CPT0123530003
Tumor
0.0
CPT0218830004
Tumor
0.0
CPT0205890003
Tumor
0.0
CPT0064890003
Tumor
0.0
CPT0225760003
Tumor
0.0
CPT0125220003
Tumor
0.0
CPT0093590003
Tumor
0.0
CPT0218890004
Tumor
0.0
CPT0206880003
Tumor
0.0
CPT0092440003
Tumor
0.0
CPT0209440003
Tumor
0.0
CPT0225730003
Tumor
0.0
CPT0071100003
Tumor
0.0
CPT0217430008
Tumor
0.0
CPT0182550003
Tumor
-0.1
CPT0206000004
Tumor
-0.1
CPT0168270003
Tumor
-0.1
CPT0002410011
Tumor
-0.1
CPT0199770003
Tumor
-0.1
CPT0189570004
Tumor
-0.1
CPT0168480003
Tumor
-0.1
CPT0206110003
Tumor
-0.1
CPT0204400003
Normal
-0.1
CPT0189850004
Tumor
-0.1
CPT0196850003
Tumor
-0.1
CPT0104330003
Tumor
-0.1
CPT0218770003
Tumor
-0.1
CPT0217880003
Tumor
-0.2
CPT0224600003
Tumor
-0.2
CPT0168720003
Tumor
-0.2
CPT0171580008
Tumor
-0.2
CPT0206450003
Tumor
-0.2
CPT0204340003
Normal
-0.2
CPT0218670003
Tumor
-0.2
CPT0093450003
Tumor
-0.2
CPT0204370003
Normal
-0.2
CPT0206670004
Tumor
-0.2
CPT0204360003
Normal
-0.3
CPT0206330003
Tumor
-0.3
CPT0217190003
Tumor
-0.3
CPT0162140003
Tumor
-0.3
CPT0218960004
Tumor
-0.3
CPT0204420003
Normal
-0.3
CPT0204390003
Normal
-0.3
CPT0167750004
Tumor
-0.3
CPT0201710003
Tumor
-0.3
CPT0207090003
Tumor
-0.3
CPT0161730003
Tumor
-0.3
CPT0224330003
Tumor
-0.4
CPT0204350003
Normal
-0.4
CPT0104220003
Tumor
-0.4
CPT0189250003
Tumor
-0.4
CPT0218330004
Tumor
-0.5
CPT0167860004
Tumor
-0.5
CPT0204410003
Normal
-0.6
CPT0207030003
Tumor
-0.6
CPT0204380003
Normal
-0.6
CPT0190240004
Tumor
-0.7
CPT0204330003
Normal
-0.8
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.
Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.